Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy
Open Access
- 20 May 2022
- journal article
- research article
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (5) , 547-552
Abstract
Kim SH, et al. J Clin Neurol. 2022 Sep;18(5):547-552. https://doi.org/10.3988/jcn.2022.18.5.547Keywords
This publication has 9 references indexed in Scilit:
- Cannabidiol (CBD) and cognition in epilepsyEpilepsy & Behavior, 2021
- Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in KoreaJournal of Korean Medical Science, 2020
- Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsyEpilepsy & Behavior, 2019
- Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2018
- Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open‐label clinical study with cannabidiolEpilepsia, 2017
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet SyndromeNew England Journal of Medicine, 2017
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialThe Lancet Neurology, 2016
- Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsyEpilepsy & Behavior, 2015
- Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsyEpilepsy & Behavior, 2013